Neo Ivy Capital Management’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-38,961
| Closed | -$1.2M | – | 438 |
|
|
2023
Q2 | $1.2M | Buy |
+38,961
| New | +$1.2M | 0.63% | 36 |
|
|
2022
Q4 | $277K | Buy |
7,014
+660
| +10% | +$26.1K | 0.19% | 200 |
|
|
2022
Q3 | $255K | Buy |
+6,354
| New | +$255K | 0.67% | 34 |
|
|
2022
Q2 | – | Sell |
-6,692
| Closed | -$260K | – | 581 |
|
|
2022
Q1 | $260K | Buy |
+6,692
| New | +$260K | 0.23% | 156 |
|
|
2021
Q4 | – | Sell |
-1,102
| Closed | -$54K | – | 606 |
|
|
2021
Q3 | $54K | Buy |
+1,102
| New | +$54K | 0.06% | 312 |
|
|
2021
Q1 | – | Sell |
-5,736
| Closed | -$287K | – | 604 |
|
|
2020
Q4 | $287K | Buy |
5,736
+3,912
| +214% | +$196K | 0.32% | 107 |
|
|
2020
Q3 | $76K | Buy |
1,824
+722
| +66% | +$30.1K | 0.08% | 317 |
|
|
2020
Q2 | $54K | Buy |
+1,102
| New | +$54K | 0.06% | 312 |
|